International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Résumé
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Neurology
- Thématique
- Multiple Sclerosis Research Studies
- Domaine
- Medicine
- Établissements canadiens
- —
- Organismes subventionnaires
- Chugai PharmaceuticalMitsubishi Tanabe Pharma CorporationNational Eye InstituteAstellas PharmaNovartis PharmaMinistry of Education, Science and TechnologyMultiple Sclerosis Society of CanadaEuropean Committee for Treatment and Research in Multiple SclerosisAlexion PharmaceuticalsNational Institute of Neurological Disorders and StrokeTeijin PharmaTeva Pharmaceutical IndustriesAcorda TherapeuticsViropharmaGlaxoSmithKlineBiogenOno PharmaceuticalEisaiNational Institutes of HealthGuthy-Jackson Charitable FoundationDaiichi Sankyo EuropeSanofi
- Mots-clés
- Neuromyelitis opticaMedicineMultiple sclerosisNeuroimagingConsensus conferenceSpinal cordSerologyPathologyOptic neuritisSpectrum disorderAquaporin 4AntibodyImmunologyInternal medicinePsychiatry
- Résumé présent dans OpenAlex
- oui